Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Chimeric Antigen Receptor Therapy in Lymphoma
Introduction Clinical trials of CD19 chimeric antigen receptor (CAR) T-cells have demonstrated promising survival outcomes and response rates in relapsed and/or refractory (r/r) non-Hodgkin lymphoma (NHL), providing a potentially curative treatment option for these heterogeneous, aggressive malignancies. There are currently…